(Q45937530)

18 December 2017

title

Influence of clinical and genetic factors on warfarin dose requirements among Japanese patients. (English)

1 reference

18 December 2017

1 reference

12

1 reference

18 December 2017

author name string

Masako Ohno

1

1 reference

18 December 2017

Akiko Yamamoto

2

1 reference

18 December 2017

Ayumu Ono

3

1 reference

18 December 2017

Genta Miura

4

1 reference

18 December 2017

Masanobu Funamoto

5

1 reference

18 December 2017

Yasuhiko Takemoto

6

1 reference

18 December 2017

Kinya Otsu

7

1 reference

18 December 2017

Yasushi Kouno

8

1 reference

18 December 2017

Tomoko Tanabe

9

1 reference

18 December 2017

Yuiko Masunaga

10

1 reference

18 December 2017

Shinpei Nonen

11

1 reference

18 December 2017

Junichi Azuma

13

1 reference

18 December 2017

publication date

7 July 2009

1 reference

18 December 2017

European Journal of Clinical Pharmacology

published in

1 reference

18 December 2017

volume

65

1 reference

18 December 2017

issue

11

1 reference

18 December 2017

page(s)

1097-1103

1 reference

18 December 2017

https://scigraph.springernature.com/pub.10.1007/s00228-009-0685-9

exact match

0 references

1 reference

https://api.crossref.org/works/10.1007%2FS00228-009-0685-9

Optimal intensity of warfarin therapy for secondary prevention of stroke in patients with nonvalvular atrial fibrillation : a multicenter, prospective, randomized trial. Japanese Nonvalvular Atrial Fibrillation-Embolism Secondary Prevention Cooperat

21 January 2018

1 reference

Crossref

https://api.crossref.org/works/10.1007%2FS00228-009-0685-9

Genetic determinants of dose and clinical outcomes in patients receiving oral anticoagulants

21 January 2018

1 reference

12 December 2020

A formula to estimate the approximate surface area if height and weight be known. 1916.

1 reference

12 December 2020

Genotypes of the cytochrome p450 isoform, CYP2C9, and the vitamin K epoxide reductase complex subunit 1 conjointly determine stable warfarin dose: a prospective study.

1 reference

12 December 2020

Clinical consequences of cytochrome P450 2C9 polymorphisms

1 reference

12 December 2020

Association between CYP2C9 genetic variants and anticoagulation-related outcomes during warfarin therapy

1 reference

12 December 2020

Influence of polymorphisms in the factor VII gene promoter on activated factor VII levels and on the risk of myocardial infarction in advanced coronary atherosclerosis

1 reference

12 December 2020

VKORC1 gene variations are the major contributors of variation in warfarin dose in Japanese patients.

1 reference

12 December 2020

Two common functional polymorphisms in the promoter region of the coagulation factor VII gene determining plasma factor VII activity and mass concentration

1 reference

12 December 2020

CYP2C9*3 allelic variant and bleeding complications

1 reference

12 December 2020

Genetic modulation of oral anticoagulation with warfarin

1 reference

12 December 2020

A novel functional VKORC1 promoter polymorphism is associated with inter-individual and inter-ethnic differences in warfarin sensitivity.

1 reference

12 December 2020

Warfarin dose requirement for patients with both VKORC1 3673A/A and CYP2C9*3/*3 genotypes

1 reference

12 December 2020

Polymorphisms of the factor VII gene associated with the low activities of vitamin K-dependent coagulation factors in one-month-old infants

1 reference

12 December 2020

The influence of sequence variations in factor VII, gamma-glutamyl carboxylase and vitamin K epoxide reductase complex genes on warfarin dose requirement

1 reference

12 December 2020

Contribution of age, body weight, and CYP2C9 and VKORC1 genotype to the anticoagulant response to warfarin: proposal for a new dosing regimen in Chinese patients

1 reference

12 December 2020

Genetic polymorphism of cytochrome P450s, CYP2C19, and CYP2C9 in a Japanese population

1 reference

12 December 2020

Influence of coagulation factor, vitamin K epoxide reductase complex subunit 1, and cytochrome P450 2C9 gene polymorphisms on warfarin dose requirements.

1 reference

12 December 2020

Pharmacogenetics of CYP2C9 and interindividual variability in anticoagulant response to warfarin

1 reference

12 December 2020

Cytochrome P450 2C9 polymorphisms: a comprehensive review of the in-vitro and human data.

1 reference

12 December 2020

Association of polymorphisms in the cytochrome P450 CYP2C9 with warfarin dose requirement and risk of bleeding complications

1 reference

12 December 2020

Association of VKORC1 and CYP2C9 polymorphisms with warfarin dose requirements in Japanese patients

1 reference

12 December 2020

ACC/AHA/ESC 2006 Guidelines for the Management of Patients With Atrial Fibrillation

1 reference

12 December 2020

Human P450 metabolism of warfarin

1 reference

12 December 2020

Estimation of warfarin maintenance dose based on VKORC1 (-1639 G>A) and CYP2C9 genotypes

1 reference

12 December 2020

Genotypes of vitamin K epoxide reductase, gamma-glutamyl carboxylase, and cytochrome P450 2C9 as determinants of daily warfarin dose in Japanese patients.

1 reference

12 December 2020

Randomized trial of genotype-guided versus standard warfarin dosing in patients initiating oral anticoagulation

1 reference

12 December 2020

Association of pharmacokinetic (CYP2C9) and pharmacodynamic (factors II, VII, IX, and X; proteins S and C; and gamma-glutamyl carboxylase) gene variants with warfarin sensitivity

1 reference

12 December 2020

Evaluation of genetic factors for warfarin dose prediction

1 reference

12 December 2020

10.1007/S00228-009-0685-9

Identifiers

DOI

1 reference

18 December 2017

Dimensions Publication ID

1011394285

0 references

1 reference

18 December 2017